Date: January 14, 2022  Administrative Circular: 2022:03

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
    Part 4 – Biological Products

Part 4 – Biological Products
COVID-19 Vaccines

   COVID-19 Vaccine Eligibility
   Footnote C has been added to booster doses to indicate that pregnant persons may receive
   a booster dose at least 8 weeks after completion of a primary COVID-19 vaccine series.

   COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

   • Doses and Schedule:
     o The Health Canada authorized interval of 21 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.
     o The recommendation that the vaccine series should be completed with the same COVID-19 vaccine product has been removed from the footnotes.
     o Footnote G has been revised to indicate that the 8 week minimum interval from completion of the primary series to a booster dose applies to pregnant persons.

Please remove page numbers: 1-2 dated January 7, 2022
Please add new page numbers: 1-2 dated January 14, 2022
COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

- **Doses and Schedule:**
  - The Health Canada authorized interval of 21 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.

- **Administration:**
  - Footnote B has been added to indicate that the date printed on the vial and carton is the date of manufacture and that the vaccine must be used within 6 months of this date when stored at -90°C to -60°C.

Please remove page numbers: 1-5 dated December 15, 2021  
Please add new page numbers: 1-5 dated January 14, 2022

COVID-19 mRNA Vaccine SPIKEVAX (Moderna)

- **Doses and Schedule:**
  - The Health Canada authorized interval of 28 days between dose 1 and 2 has been moved to Footnote C and the preferred interval of 8 weeks has been moved in its place under DOSES AND SCHEDULE.
  - The recommendation that the vaccine series should be completed with the same COVID-19 vaccine product has been removed from the footnotes.
  - Footnote G has been revised to indicate that the 8 week minimum interval from completion of the primary series to a booster dose applies to pregnant persons.

- **Administration:**
  - Footnote C has been updated to include content regarding the recent 2 month shelf life extension for certain lots of Moderna COVID-19 mRNA vaccine with expiry dates of February 15, 2022 through August 31, 2022. The new expiry dates can be found in the Health Canada alert.

Please remove page numbers: 1-5 dated December 31, 2021  
Please add new page numbers: 1-5 dated January 14, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- **Administration:**
  - Content has been revised to include frozen storage time and duration at -25°C to -15°C. Guidance regarding thawing parameters has also been included.

Please remove page numbers: 1-4 dated January 7, 2022  
Please add new page numbers: 1-4 dated January 14, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACP M
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:  
Provincial Health Officer  
Dr. Bonnie Henry  

Dr. Reka Gustafson  
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer  

Deputy Provincial Health Officer  
Dr. Martin Lavoie  

BC Ministry of Health, Population & Public Health Division:  
Brian Sagar  
Senior Director Communicable Disease, Population and Public Health Division  

Bernard Achampong  
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division